GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lexaria Bioscience LEXX · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.54

+0.89%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$705,923

FY2016FY2025

Net income

−$11.9m

FY2016FY2025

Free cash flow

−$10.5m

FY2016FY2025

Shareholders' equity

$3.0m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$705,923$464,278$226,208$255,397$722,738$384,543$222,610$433,287$63,639$40,718
Research and development$8.2m$2.4m$3.7m$1.8m$1.3m$387,074$555,730$492,864$54,185$9,024
Operating income−$11.9m−$5.8m−$6.5m−$6.6m−$5.7m−$4.1m−$4.1m−$6.6m−$1.9m−$1.2m
Net income−$11.9m−$5.8m−$6.7m−$7.3m−$4.0m−$3.9m−$4.1m−$6.6m−$1.9m−$1.2m
Diluted earnings per share-8.35-5.22-11.05-18.32-10.55-19.66-23.32-38.95-12.26-10.57

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$4.2m$8.9m$3.1m$7.8m$13.3m$2.8m$2.7m$2.4m$2.9m$566,638
Cash and short-term investments$2.0m$6.6m$1.5m$6.2m$11.8m$1.3m$1.3m$1.7m$2.5m$93,409
Total liabilities$1.6m$1.2m$403,908$201,437$203,265$345,980$184,507$43,640$92,347$478,881
Debt$109,320$137,366$163,967$49,988$97,319$156,101—$7,855$42,690$45,000
Shareholders' equity$3.0m$8.0m$3.0m$7.9m$13.3m$2.5m$2.4m$2.4m$3.0m$266,045
Shares outstanding1m1m1m0m0m0m0m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$10.5m−$5.0m−$5.9m−$4.9m−$4.0m−$2.6m−$3.0m−$2.5m−$1.5m−$660,856
Capital spending−$24,643−$43,017−$169,610−$49,191−$79,493−$33,645−$769,165−$85,399−$9,699−$20,102
Free cash flow−$10.5m−$5.0m−$6.1m−$4.9m−$4.1m−$2.7m−$3.8m−$2.6m−$1.6m−$680,958

Latest quarters

By quarter end

May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024
Revenue—$20,000—$174,000$174,000$174,000$183,923$84,000
Operating income−$2.0m−$1.5m−$1.6m−$2.7m−$3.8m−$2.8m−$2.7m−$2.2m
Net income−$2.0m−$1.4m−$1.6m−$2.7m−$3.8m−$2.7m−$2.7m−$2.2m
Diluted earnings per share-1.20-0.88-1.12-1.89-2.66-1.90-2.43-1.97
Cash from operations−$1.0m−$2.0m—−$2.0m−$3.0m−$1.0m−$2.0m−$1.0m
Total assets$4.8m$6.5m$6.1m$4.2m$6.7m$8.7m$9.8m$8.9m
Cash and short-term investments$3.6m$5.3m$4.4m$2.0m$4.6m$6.5m$8.1m$6.6m
Debt$33,035$32,060$31,101$30,417$29,872$29,337$28,812$28,047
Shareholders' equity$4.7m$6.6m$4.9m$3.0m$5.6m$7.1m$9.8m$8.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue40.3%12.9%47.3%
Operating income21.5%23.4%19.9%
Net income17.9%24.8%21.0%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1506.9%-1863.8%-1472.3%-1593.0%
Net margin-1512.3%-1915.0%-1435.0%-1560.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-0.7-3.7-1.0-1.2-3.5
Price to sales11.546.330.735.219.6

Share price return

Finished calendar years

20252024202320222021
Return-68%50%-42%-42%-7%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 15-to-1 reverse split · 3 Aug 2026
  • 30-to-1 reverse split · 12 Jan 2021
  • 1.1-for-1 split · 16 Dec 2015
  • 4-to-1 reverse split · 23 Jun 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.